Bob Wasserman has been following healthcare and biotech stocks for over 30 years, with a bias toward value investing. He has been quoted and appeared in a number of print and media outlets, and his education includes degrees from MIT and the University of Chicago. He currently lives in Florida.
Allergan's most-recent quarterly financial report for Q4/2016 showed solid results.
Oculus Innovative Sciences represents a good buy for value investors or cash-rich companies such as Allergan.
Iora Health just raised $75 million in funding and has 34 clinics in 11 states, including Boston and New York.
Although many biotechnology stocks have fallen this year due to disappointing clinical trial results, what is the deal with this stock that is down precipitously despite encouraging R&D news?
Momenta may be a good option for value-oriented investors, while Coherus may be better for those who prefer a company that is likely to gain momentum.
The promotion of Paul Campanelli to CEO indicates a change in the company's focus from acquiring other firms to its roots as a generic pharmaceutical firm.
What to do with $40 billion? That is the question facing Allergan (AGN). One biotechnology stock which stands out as a potential target for Allergan is Applied Genetic Technologies (AGTC).
Catalent and West Pharmaceutical Services provide products and services to biotech and pharmaceutical firms. Intellipharmaceutics is a small-cap firm on the rise.
The Baudette, Minn.-based company has 79 products generating about $4 billion in sales and a number of other promising therapies in its pipeline.
Even though it has huge, better-known rivals, Exactech (EXAC) is the best-performing stock in the orthopedic products sector this year.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.